Anti-cancer agent and mitochondrial division inhibitor combination
作者： Hussain Afthab , Maddock Helen , Gharanei Ahmed Mayel
DOI:
关键词: Mitoxantrone 、 Anthracycline 、 Daunorubicin 、 Idarubicin 、 Pharmacology 、 Doxorubicin 、 Erlotinib 、 Chemistry 、 Tyrosine-kinase inhibitor 、 Valrubicin
摘要: A pharmaceutical composition comprises (i) an anti-cancer agent; and (ii) a mitochondrial division inhibitor optionally together with one or more pharmaceutically acceptable carriers, diluents excipients. The agent may be anthracycline-based antibiotic selected from the group consisting of doxorubicin, daunorubicin, epirubicin, idarubicin valrubicin. variant, derivative analogue antibiotic, in particular, anthracenedione, such as mitoxantrone. tyrosine kinase erlotinib, gefitinib, imatinib sunitinib. Preferably is cell-permeable quinazolinone compound capable inhibiting cell division, particular mdivi-1 (3-​(2,4-​Dichloro-​5-​methoxyphenyl)​-​2-​sulfanyl-​4(3H)​-​quinazolinone), thereof. for use treatment cancer. co-treatment doxorubicin provided.
lens.org 参考文章(3)
Bennett Van Houten, Wei Qian, Inhibition of dynamin related protein 1 to promote cell death ,(2012)
Alan S. Maisel, Pam R. Taub, Guillermo Ceballos, George F. Schreiner, Francisco Villarreal, Methods and compositions for treatment of mitochondrial toxicity ,(2012)
Balaraman Kalyanaraman, Joy Joseph, Shasi Kalivendi, Methods for reducing anthracycline-induced toxicity ,(2007)